Intercept Pharmaceuticals, Inc. (ICPT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ICPT POWR Grades
- ICPT scores best on the Quality dimension, with a Quality rank ahead of 96.93% of US stocks.
- ICPT's strongest trending metric is Value; it's been moving up over the last 179 days.
- ICPT's current lowest rank is in the Sentiment metric (where it is better than 8.73% of US stocks).
ICPT Stock Summary
- Intercept Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 3.31% of US listed stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -2.82 for Intercept Pharmaceuticals Inc; that's greater than it is for only 3.5% of US stocks.
- Intercept Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 22.61%, greater than the shareholder yield of 92.25% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Intercept Pharmaceuticals Inc, a group of peers worth examining would be CLXT, DAIO, AKBA, IIVI, and MRIN.
- Visit ICPT's SEC page to see the company's official filings. To visit the company's web site, go to www.interceptpharma.com.
ICPT Valuation Summary
- ICPT's price/sales ratio is 1.5; this is 60.53% lower than that of the median Healthcare stock.
- ICPT's price/sales ratio has moved down 98.5 over the prior 108 months.
- ICPT's EV/EBIT ratio has moved up 12.1 over the prior 108 months.
Below are key valuation metrics over time for ICPT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ICPT | 2021-08-31 | 1.5 | -2.4 | -2.9 | -7.6 |
| ICPT | 2021-08-30 | 1.4 | -2.4 | -2.8 | -7.5 |
| ICPT | 2021-08-27 | 1.4 | -2.4 | -2.8 | -7.5 |
| ICPT | 2021-08-26 | 1.3 | -2.2 | -2.6 | -7.2 |
| ICPT | 2021-08-25 | 1.3 | -2.2 | -2.6 | -7.2 |
| ICPT | 2021-08-24 | 1.3 | -2.3 | -2.7 | -7.3 |
ICPT Growth Metrics
- The 2 year revenue growth rate now stands at 86.74%.
- Its 5 year net income to common stockholders growth rate is now at -10.73%.
- Its 2 year net cashflow from operations growth rate is now at 8.98%.
The table below shows ICPT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 363.468 | -41.639 | -91.426 |
| 2021-09-30 | 354.332 | -61.467 | -107.293 |
| 2021-06-30 | 341.026 | -106.584 | -170.13 |
| 2021-03-31 | 321.699 | -125.945 | -222.317 |
| 2020-12-31 | 312.69 | -170.026 | -274.88 |
| 2020-09-30 | 300.922 | -214.535 | -320.891 |
ICPT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ICPT has a Quality Grade of B, ranking ahead of 77.14% of graded US stocks.
- ICPT's asset turnover comes in at 0.66 -- ranking 47th of 682 Pharmaceutical Products stocks.
- GBT, AVDL, and SYRS are the stocks whose asset turnover ratios are most correlated with ICPT.
The table below shows ICPT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.660 | 0.992 | -0.066 |
| 2021-06-30 | 0.616 | 0.988 | -0.139 |
| 2021-03-31 | 0.552 | 0.984 | -0.191 |
| 2020-12-31 | 0.506 | 0.983 | -0.239 |
| 2020-09-30 | 0.455 | 0.977 | -0.277 |
| 2020-06-30 | 0.397 | 0.980 | -0.282 |
ICPT Price Target
For more insight on analysts targets of ICPT, see our ICPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $31.63 | Average Broker Recommendation | 1.92 (Hold) |
ICPT Stock Price Chart Interactive Chart >
ICPT Price/Volume Stats
| Current price | $14.13 | 52-week high | $20.50 |
| Prev. close | $13.81 | 52-week low | $10.81 |
| Day low | $13.46 | Volume | 546,900 |
| Day high | $14.25 | Avg. volume | 894,445 |
| 50-day MA | $15.67 | Dividend yield | N/A |
| 200-day MA | $16.14 | Market Cap | 419.84M |
Intercept Pharmaceuticals, Inc. (ICPT) Company Bio
Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases. The company was founded in 2002 and is based in New York, New York.
Latest ICPT News From Around the Web
Below are the latest news stories about Intercept Pharmaceuticals Inc that investors may wish to consider to help them evaluate ICPT as an investment opportunity.
Intercept to Announce Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022NEW YORK, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2021 financial results prior to market open on Wednesday, March 2, 2022. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results. |
Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseIntercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
Shareholders in Intercept Pharmaceuticals (NASDAQ:ICPT) are in the red if they invested five years agoLong term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut... |
3 Biotech Stocks That Are too Cheap to IgnoreThe stock market is giving investors some real healthcare bargains right now. Patrick Bafuma (Intercept Pharma): I will freely admit that Intercept Pharma has been a dog through the years, down a maddening 87% over the last five years. A significant portion of Intercept's drop was also due to a complete response letter in June 2020 for the treatment of non-alcoholic steatohepatitis (NASH). |
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Axsome Therapeutics (AXSM), Intercept Pharma (ICPT) and Check-Cap (CHEK)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axsome Therapeutics (AXSM – Research Report), Intercept Pharma (ICPT – Research Report) and Check-Cap (CHEK – Research Report). Axsome Therapeutics (AXSM) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics today and set a price target of $180.00. The company's shares closed last Monday at $30.52. According to TipRanks. |
ICPT Price Returns
| 1-mo | -13.74% |
| 3-mo | -20.75% |
| 6-mo | -9.89% |
| 1-year | N/A |
| 3-year | -82.44% |
| 5-year | -88.38% |
| YTD | -13.26% |
| 2021 | -34.05% |
| 2020 | -80.07% |
| 2019 | 22.95% |
| 2018 | 72.53% |
| 2017 | -46.23% |
Continue Researching ICPT
Want to do more research on Intercept Pharmaceuticals Inc's stock and its price? Try the links below:Intercept Pharmaceuticals Inc (ICPT) Stock Price | Nasdaq
Intercept Pharmaceuticals Inc (ICPT) Stock Quote, History and News - Yahoo Finance
Intercept Pharmaceuticals Inc (ICPT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...